Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB (GEN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 04:59:53 pm
1068.5 DKK   +0.09%
11/09GENMAB A/S : quaterly earnings release
08/03GENMAB A/S : half-yearly earnings release
05/03GENMAB A/S : quaterly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
1025(c) 1024(c) 1056.5(c) 1067.5(c) 1068.5(c) Last
218 687 139 312 197 075 181 195 179 413 Volume
+2.73% -0.10% +3.17% +1.04% +0.09% Change
More quotes
Financials (DKK)
Sales 2018 2 937 M
EBIT 2018 1 404 M
Net income 2018 1 336 M
Finance 2018 5 803 M
Yield 2018 -
Sales 2019 4 051 M
EBIT 2019 2 190 M
Net income 2019 2 022 M
Finance 2019 7 709 M
Yield 2019 -
P/E ratio 2018 49,65
P/E ratio 2019 33,32
EV / Sales2018 20,4x
EV / Sales2019 14,3x
Capitalization 65 710 M
More Financials
Company
Genmab specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (47.9%); - income from research and development (44.8%); - other... 
Sector
Biotechnology & Medical Research
Calendar
02/20 | 05:00pmEarnings Release
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
12/11GENMAB : Grant of Restricted Stock Units to Board Members, Management and Employ..
AQ
12/10GENMAB : Grant of Restricted Stock Units to Board Members, Management and Employ..
AQ
12/04GENMAB : to Hold R&D Update and 2018 ASH Data Review Meeting
AQ
11/26GENMAB : to Hold R&D Update and 2018 ASH Data Review Meeting
AQ
11/22GENMAB A/S : has published its Articles of Association
AQ
11/21GENMAB A/S : - Data from Phase III MAIA Study of Daratumumab Accepted for Presen..
AQ
11/21GENMAB : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/21GENMAB : Data from Phase III MAIA Study of Daratumumab Accepted for Presentation..
AQ
11/20GENMAB : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/20GENMAB A/S : - CHMP Issues Positive Opinion on Split Dosing Regimen for DARZALEX
AQ
More news
Analyst Recommendations on GENMAB
More recommendations
Sector news : Bio Therapeutic Drugs
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Bio Therapeutic Drugs
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 1 287  DKK
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB3.84%9 952
GILEAD SCIENCES-8.47%84 823
VERTEX PHARMACEUTICALS15.72%43 460
REGENERON PHARMACEUTICALS1.39%40 527
SAREPTA THERAPEUTICS INC114.81%7 987
NEUROCRINE BIOSCIENCES, INC.-8.06%6 469